Author + information
Background: EUROASPIRE IV is a cross-sectional survey undertaken in 26 European countries aiming to determine whether the Joint European Societies guidelines on cardiovascular (CVD) prevention are being followed in everyday clinical practice.
Methods and Results: Patients <80 years with 1) coronary disease or 2) identified as high CVD risk on the basis of being on blood pressure and/or lipid-lowering medication and/or having diabetes, were identified and interviewed at least six months after the recruiting coronary event or the start of medication.
Results: A total of 7998 coronary patients (24% females) and 4579 high CVD risk individuals (59% women) were interviewed. Overall, the prevalence of smoking, obesity (BMI≥30 kg/m2) and central obesity (waist circumference≥102 cm in men or ≥88 cm in women) was similar in coronary patients (17%, 38%, 58%) and high CVD risk individuals (17%, 44%, 64%). The medical risk factor control was poor in both groups. Among those on blood pressure lowering medication 53% of coronary patients and 43% of high CVD risk individuals achieved the target of < 140/90mm Hg (< 140/80mm Hg in people with self-reported diabetes). The LDL-cholesterol goal of <1.8mmol/l was attained by 21% of coronary patients while only 33% of high CVD risk individuals achieved the target of < 2.5 mmol/L. Among people treated for type 2 diabetes mellitus, 53% of coronary patients and 59% of high CVD risk individuals achieved the glycated haemoglobin (HbA1c) target of < 7.0%.
Conclusions: A significant gap still exists between the prevention guidelines and their adherence and control of CVD risk factors in coronary and high CVD risk patients in Europe. A large majority does not achieve the guideline standards for primary and secondary prevention with high prevalences of persistent smoking, obesity and central obesity and inadequate control of blood pressure, lipids and glucose. A modern preventive cardiology programme is urgently needed to achieve healthier lifestyles, better risk factor control and optimize the prognosis in all coronary patients and people at high CVD risk.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Innovations in Cardiovascular Risk Assessment and Reduction
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1235-047
- 2017 American College of Cardiology Foundation